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Abstract
Introduction: Little information exists about the impact of acute kidney injury (AKI) in critically ill patients with the
pandemic 2009 influenza A (H1N1) virus infection.
Methods: We conducted a prospective, observational, multicenter study in 148 Spanish intensive care units (ICUs).
Patients with chronic renal failure were excluded. AKI was defined according to Acute Kidney Injury Network (AKIN)
criteria.
Results: A total of 661 patients were analyzed. One hundred eighteen (17.7%) patients developed AKI; of these, 37
(31.4%) of the patients with AKI were classified as AKI I, 15 (12.7%) were classified as AKI II and 66 (55.9%) were classified
as AKI III, among the latter of whom 50 (75.7%) required continuous renal replacement therapy. Patients with AKI had a
higher Acute Physiology and Chronic Health Evaluation II score (19.2 ± 8.3 versus 12.6 ± 5.9; P < 0.001), a higher
Sequential Organ Failure Assessment score (8.7 ± 4.2 versus 4.8 ± 2.9; P < 0.001), more need for mechanical ventilation
(MV) (87.3% versus 56.2%; P < 0.01, odds ratio (OR) 5.3, 95% confidence interval (CI) 3.0 to 9.4), a greater incidence of
shock (75.4% versus 38.3%; P < 0.01, OR 4.9, 95% CI, 3.1 to 7.7), a greater incidence of multiorgan dysfunction syndrome
(92.4% versus 54.7%; P < 0.01, OR 10.0, 95% CI, 4.9 to 20.21) and a greater incidence of coinfection (23.7% versus 14.4%;
P < 0.01, OR 1.8, 95% CI, 1.1 to 3.0). In survivors, patients with AKI remained on MV longer and ICU and hospital length
of stay were longer than in patients without AKI. The overall mortality was 18.8% and was significantly higher for AKI
patients (44.1% versus 13.3%; P < 0.01, OR 5.1, 95% CI, 3.3 to 7.9). Logistic regression analysis was performed with AKIN
criteria, and it demonstrated that among patients with AKI, only AKI III was independently associated with higher ICU
mortality (P < 0.001, OR 4.81, 95% CI 2.17 to 10.62).
Conclusions: In our cohort of patients with H1N1 virus infection, only those cases in the AKI III category were
independently associated with mortality.
Introduction
The pandemic 2009 influenza A (H1N1) virus infection
was first described in Mexico in April 2009, and several
reports have been published regarding the presentation
of this disease with severe acute respiratory symptoms
in hospitalized patients [1]. However, the information
regarding the incidence and impact of renal failure
among these patients remains scarce. The World Health
Organization (WHO) warned physicians that patients
H1N1 virus infection might develop renal impairment
ranging from just mild disease to the need for renal
replacement therapy (RRT) [1-5].
In critical care settings, many studies are limited
because they lack a uniform definition of acute kidney
injury (AKI). The definition of AKI varies widely and is
predominately based on large increments of serum crea-
tinine kinase (CK), thus ignoring milder stages of AKI.
In addition, the choice of using the Acute Kidney Injury
Network (AKIN) criteria is based on the lack of reliance
on baseline CK level upon intensive care unit (ICU)
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established by a consensus of critical care and nephrol-
ogy societies worldwide [6]. The degree of AKI classified
according to AKIN criteria correlates with mortality in a
progressive fashion, emphasizing the importance of the
severity of AKI. This first globally developed AKI defini-
tion and classification incorporates the important find-
ing that small increases of serum CK levels in AKI
negatively affect patient outcome.
T h ep r e s e n ts t u d ya i m st oe v a l u a t ew h e t h e rt h ep r e -
sence of AKI in a cohort of patients hospitalized with a
severe presentation of H1N1 virus infection in the ICU
is associated with worse outcomes.
Materials and methods
S t u d yd a t aw e r eo b t a i n e df r o mav o l u n t a r yr e g i s t r yc r e -
ated by the Spanish Society of Intensive Care Medicine
(SEMICYUC) after the first reported ICU case (see
Additional file 1 for SEMICYUC working group investi-
gators). Inclusion criteria were fever >38°C; respiratory
symptoms consistent with cough, sore throat, myalgia or
influenza-like illness; acute respiratory failure requiring
ICU admission; and microbiologic confirmation of novel
H1N1 virus. Data were reported by the attending physi-
cian on the basis of medical chart reviews and radiologi-
cal and laboratory records. This study analyzes data
from the first ICU case until 31 December 2009. Chil-
dren under 15 years old were not enrolled in the study.
The study was approved by the ethical board of Joan
XXIII University Hospital, Ta r r a g o n a ,S p a i n .P a t i e n t s
remained anonymous, and the requirement for informed
consent was waived because of the observational nature
of the study. All tests and procedures were ordered by
the attending physicians.
Definitions
The following variables were recorded: demographic
data, comorbidities, time of illness onset and hospital
admission, time to first dose of antiviral delivery, micro-
biologic findings and chest radiologic findings at ICU
admission. Intubation and mechanical ventilation (MV)
requirements, adverse events during ICU stay (for exam-
ple, the need for vasopressor drugs or renal replacement
therapies) and laboratory findings at ICU admission were
also recorded. To determine the severity of illness, the
Acute Physiology and Chronic Health Evaluation II
(APACHE II) score [7] was determined in all patients
within 24 hours of ICU admission. Organ failure was
assessed using the Sequential Organ Failure Assessment
(SOFA) scoring system [8]. Obese patients were defined
as those with a body mass index (BMI) over 30 kg/m
2.
Primary viral pneumonia was defined in patients pre-
senting illness with acute respiratory distress and unequi-
vocal alveolar opacities involving two or more lobes with
negative respiratory and blood bacterial cultures during
the acute phase of influenza virus [2]. Nasopharyngeal
swab specimens were collected for respiratory viruses at
hospital admission, and lower respiratory secretions were
also obtained from intubated patients. Real-time poly-
merase chain reaction (RT-PCR) testing was performed
in accordance with the published guidelines from the
Centers for Disease Control and Prevention (CDC) [9].
Novel influenza A H1N1 testing was performed in each
institution, or centralized in a reference laboratory when
not available. A confirmed case was defined as an acute
respiratory illness with laboratory-confirmed pandemic
H1N1 virus infection identified by RT-PCR or viral
culture [10]. Only confirmed cases were included in the
current study.
Community-acquired respiratory coinfection (CARC)
was defined as any infection diagnosed within the first
2 days of hospitalization. Infections occurring later were
considered nosocomial [11]. Patients who presented
healthcare-associated pneumonia were excluded from
the present study [12]. Patients were admitted to the
ICU either because they were potential candidates for
mechanical ventilation and/or because they were judged
to be in an unstable condition requiring intensive medi-
cal or nursing care [13,14].
Oseltamivir was administered orally in accordance
with CDC recommendations, and the regimen (150 mg
per 24 hours or 300 mg per 24 hours) was chosen by
the attending physician [15]. The ICU admission criteria
and treatment decisions for all patients, including deter-
mination of the need for intubation, the dosage of RRT
and the type of antibiotic and antiviral therapy adminis-
tered were not standardized and were decided by the
attending physician.
The AKI stages in critically ill patients with H1N1 virus
infection were diagnosed according to the glomerular fil-
tration rate criteria of the current AKIN definitions [6].
Information in regard to urine output was not used in the
present manuscript. Diagnostic criteria for AKI were an
abrupt (within 48 hours) reduction in kidney function,
currently defined as an absolute increase in serum CK
level of ≥0.3 mg/dl, a percentage increase in serum CK
level of ≥50% (1.5-fold greater than baseline) or a reduc-
tion in urine output (documented oliguria of <0.5 ml/kg/
hour for more than 6 hours) [6]. The severity of AKI was
classified as stage I (serum CK increase of >150% to 200%
(1.5- to twofold increase) or ≥0.3 mg/dl), stage II (serum
CK increase of >200% to 300% (more than two- to three-
fold)) and stage III (serum CK increase of >300% (more
than threefold) or the need for RRT). Alternatively, stage
III was defined by an increase of serum CK 0.5 mg/dl
from baseline serum CK values of 4.0 mg/dl. The CK cri-
teria describe changes in renal function without specifying
the direction of change. We performed an analysis of the
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of AKI was always initiated when needed for the following
indications: pulmonary edema, oliguria (defined as urine
output <0.5 ml/kg body weight per hour for >6 hours),
metabolic acidosis or hyperkalemia not responding to con-
ventional treatment and uremia defined as urea nitrogen
of >100 mg/dl. RRT was available 24 hours per day, and
no patient requiring RRT was denied RRT on the basis of
futility. All pairs of CK levels were taken within 48-hour
periods and were analyzed during the course of ICU
admission as the maximum AKIN stage was used.
Statistical analysis
Discrete variables are expressed as counts (percentages)
and continuous variables are expressed as means ± stan-
dard deviations (SDs) or medians with the 25th to 75th
interquartile ranges (IQRs). For the demographic and
clinical characteristics of the patients, differences
between groups were assessed using the c
2 test and Fish-
er’s exact test for categorical variables and the Student’s
t-test or Mann-Whitney U test for continuous variables.
Variables significantly associated with mortality in the
univariate analysis were entered into the regression
model. To avoid spurious associations, variables entered
into the regression models were those with a relationship
in univariate analysis (P ≤ 0.05) or a plausible relationship
with the dependent variable. Results are presented as
odds ratios (ORs) and 95% confidence intervals (CIs).
Potential explanatory variables were checked for coli-
nearity prior to inclusion in the regression models using
the tolerance and variance inflation factor. Data analysis
was performed using SPSS for Windows 15.0 software
(SPSS, Inc., Chicago, IL, USA).
Results
A total of 968 patients from 148 Spanish ICUs were
included in the database, and, after excluding patients
with chronic kidney disease who were receiving dialysis
treatment (n = 48) and patients with incomplete data
(n = 259), a total of 661 patients were included in this
study (Figure 1). Of these, 364 patients (55.1%) were
male, the median age was 43 years (interquartile range
(IQR, 33 to 53) and 581 patients (87.9%) were under
60 years of age. The mean APACHE II score was 13.6 ±
6.7, and the mean SOFA score was 5.4 ± 3.4 on admis-
sion. Invasive MV was used in 408 (61.7%) of the
patients. All patients received antiviral therapy. Comor-
bidities excluding chronic renal failure were present in
466 patients (70.5%). The main comorbidities recorded
were obesity (n = 248, 37.5%), chronic obstructive pul-
monary disease (COPD; n = 109, 16.5%) and asthma
(n = 87, 13.2%).
One hundred eighteen patients (17.7%) developed
AKI. Patients with AKI were mostly male (65.3% versus
52.9%; P < 0.01) and had a mean age (±SD) of 43.8 ±
14.2 years. Patients with AKI presented comorbidities
more frequently than non-AKI patients (77.1% versus
69.1%; P = 0.05). Patients with AKI had higher APACHE
II scores (19.1 ± 8.3 versus 12.6 ± 5.9; P < 0.001), higher
SOFA scores (8.7 ± 4.2 versus 4.8 ± 2.9; P < 0.001),
more need of MV (87.3% versus 56.2%; P < 0.01, OR
5.3, 95% CI, 3.0 to 9.4), more presence of shock (75.4%
versus 38.3%; P < 0.01, OR 4.9, 95% CI, 3.1 to 7.7),
higher Multiple Organ Dysfunction Score (MODS)
(92.4% versus 54.7%; P < 0.01, OR 10.0, 95% CI, 4.9 to
20.21) and higher CARC (23.7% versus 14.4%; P <0 . 0 1 ,
OR 1.8, 95% CI, 1.1 to 3.0) (Table 1). Patients with AKI
showed higher C-reactive protein levels (median 28 mg/
dl; IQR 16.8 to 61.2 versus 20 IQR 12 to 42.1; P < 0.01)
and procalcitonin levels (median 2 ng/ml, IQR 0.8 to 10,
versus 0.5 ng/ml, IQR 0.1 to 1.8; P < 0.01) and CK levels
(median 170 U/L, IQR 74 to 417, versus 290 U/L, IQR
92.25 to 862; P < 0.01).
Thirty-seven (31.4%) of the patients with AKI were
classified as AKI I, 15 (12.7%) were classified as AKI II
and 66 (55.9%) were classified as AKI III, of which 50
patients (75.7%) required continuous renal replacement
therapy (CRRT). Additional clinical characteristics of
patients with H1N1 virus infection in accordance with
AKI classifications are presented in Table 2.
Among survivors, patients with AKI remained on MV
longer (13.6 ± 15.2 versus 8.4 ± 11.5 days; P = 0.003),
ICU length of stay (19.4 ± 16.5 days versus 12.6 ± 13.0
days; P < 0.0001), length of hospitalization (30.3 ± 19.9
days versus 20.5 ± 16.8 days; P < 0.0001) than non-AKI
patients (Table 3).
Overall ICU mortality was 18.8%, and this mortality
rate was significantly higher for AKI patients than for
non-AKI patients (44.1% versus 13.3%; P < 0.01, OR 5.1,
95% CI 3.3 to 7.9). AKIN categories were based on four
mutually exclusive variables. ICU mortality in patients
defined by AKIN criteria was as follows: no AKI 13.3%,
AKI I 24.3%, AKI II 33.3% and AKI III 57.6% (P < 0.0001)
(Figure 2). In addition, Table 4 shows that APACHE II,
SOFA, invasive MV, shock, MODS, hematologic disease
and bacterial coinfection were variables associated with
ICU mortality (univariate analysis). Logistic regression
analysis was performed with previous significantly asso-
ciated variables from the univariate analysis and with
AKIN categories. Multivariate analysis demonstrated that
among patients with AKI, only AKI III was independently
associated with higher ICU mortality (OR 4.81, 95% CI
2.17 to 10.62; P < 0.001) with a Hosmer-Lemeshow good-
ness of fit test of 3.44 (P = 0.903) for the model (Table 5).
In addition, with the aim of validating these results and
to avoid a survival advantage of patients who died very
early after ICU admission, logistic regression analysis was
performed excluding patients who died within the first
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307 excluded
48 Chronic Renal Failure
661 patients
307 excluded
259 with uncompleted data
661 patients
118 with Acute Kidney Injury 
37
AKI I
15
AKI II
66
AKI III
50
CRRT
Figure 1 Flowchart of critically ill patients enrolled in the study with 2009 pandemic influenza A (H1N1) virus infection.A K I ,a c u t e
kidney injury; CRRT, continuous renal replacement therapy.
Table 1 Comparison of baseline characteristics for patients with or without AKI in patients affected by pandemic 2009
influenza A (H1N1) virus infection
a
Variables Non-AKI (n = 543) AKI (n = 118) Total (n = 661) P value
Mean age, yr (±SD) 43.5 (13.9) 44.9 (15.2) 43.8 (14.2) 0.3
Male sex, n (%) 288 (53%) 77 (65.3%) 365 (55.2%) 0.01
Comorbidities, n (%)
Pregnancy 34 (6.3%) 5 (4.3%) 39 (5.9%) 0.5
COPD 90 (16.5%) 19 (16.2%) 109 (16.5%) 0.9
Asthma 76 (14.0%) 11 (9.4%) 87 (13.2%) 0.2
Heart failure 29 (5.3%) 10 (8.5%) 39 (5.9%) 0.2
Obesity 196 (36.0%) 52 (44.4%) 248 (37.5%) 0.09
Diabetes 52 (9.6%) 19 (16.2%) 71 (10.7%) 0.04
Immunosupression 17 (3.1%) 3 (2.6%) 20 (3.0%) 0.9
Hematologic disease 26 (4.8%) 8 (6.8%) 34 (5.1%) 0.3
Neuromuscular disease 21 (3.9%) 2 (1.7%) 23 (3.5%) 0.4
HIV infection 12 (2.2%) 3 (2.6%) 15 (2.3%) 0.7
aAKI, acute kidney injury; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus.
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highly consistent with the previous one (OR 5.31, 95% CI
2.37 to 11.91; P < 0.001).
Discussion
To the best of our knowledge, this is the largest study
to date focusing on AKI during the H1N1 virus pan-
demic. The main finding of the present study was that
the presence of AKI in ICU patients with a severe pre-
sentation of H1N1 virus infection was associated with
increased mortality rates. In addition, only AKI III
patients who were included showed higher rates and
were found to have an independent risk factor for ICU
mortality.
AKI is a complex disorder that occurs in a variety of
settings, with clinical manifestations ranging from a
minimal elevation in serum CK level to anuric renal fail-
ure. It is often underrecognized and is associated with
severe consequences [16]. Renal impairment is common
in ICU patients and is associated with high mortality
rates and high consumption of resources, especially in
patients who require RRT. Recent epidemiological stu-
dies have demonstrated the wide variation in etiologies
of and risk factors for AKI [17-19]. AKI occurs in
approximately 19% of patients with moderate sepsis,
23% of patients with severe sepsis and 51% of patients
with septic shock [20]. Patients who have sepsis-related
AKI have much higher mortality than patients with AKI
w h od on o th a v es e p s i s[ 2 1 ] .O s t e r m a n net al. [22]
recently demonstrated that the risk of death is higher in
patients with a worse degree of AKI, and only AKI III
was independently associated with ICU mortality.
Table 2 Selected physiologic and laboratory characteristics of patients with pandemic 2009 influenza A (H1N1) virus
infection with or without AKI and AKIN criteria
a
Variables Total Non-AKI
(n = 543)
AKI
(n = 118)
P
value
AKI I
(n = 37)
AKI II
(n = 15)
AKI III
(n = 66)
P
value
Physiologic
characteristics
Mean APACHE
II score (±SD)
13.6
(6.7)
12.6
(5.9)
19.1
(8.4)
<0.001 16.6
(6.9)
20.9
(7.4)
20.8
(9.3)
<0.001
Mean SOFA
score (±SD)
5.4
(3.5)
4.8
(2.9)
8.7
(4.2)
<0.001 4.7
(2.9)
7.7
(3.5)
9.2
(4.4)
<0.001
Invasive MV,
n (%)
408
(61.7%)
305
(56.2%)
103
(87.3%)
<0.001 28
(75.7%)
12
(80.0%)
63
(95.5%)
<0.001
Shock, n (%) 297
(44.9%)
208
(38.3%)
89
(75.4%)
<0.001 23
(62.2%)
8
(53.3%)
58
(87.9%)
<0.001
MODS, n (%) 406
(61.4%)
297
(54.7%)
109
(92.4%)
<0.001 29
(78.4%)
14
(93.3%)
66
(100.0%)
<0.001
Coinfection,
n (%)
106
(16.0%)
78
(14.4%)
28
(23.7%)
<0.01 10
(27.0%)
5
(33.3%)
13
(19.7%)
0.03
Median laboratory
findings, median
(IQR)
Leukocyte
count per mm
3
6,900
(4,000 to 11,500)
6,800
(3,925 to 11,075)
8,300
(4,300 to 14,000)
<0.01 6,770
(4,250 to 15,850)
8,850
(4,375 to 11,525)
8,200
(4,200 to 13,750)
0.5
Platelet count
per mm
3
163.5
(120 to 223.2)
166
(124 to 227)
149
(99 to 197)
0.09 160
(110 to 238)
140
(81 to 181)
149
(77.5 to 197.5)
0.02
Serum
creatinine
kinase, U/L
176.5
(75 to 474.2)
170
(74-417-75)
290
(92.25 to 862)
<0.01 199
(36 to 1,270)
218
(48 to 475)
319
(136.5 to 860.25)
0.005
Serum lactate
dehydrogenase,
IU/L
611
(366.5-1,019.7)
600
(355 to 986)
720
(402 to 1,103)
0.001 506
(305 to 954)
380
(338 to 439)
1,000
(606 to 1,527)
<0.001
Serum AST,
IU/L
53
(32 to 99)
50
(31.25 to 88.75)
64
(36.5 to 147)
0.001 47
(29.5 to 111)
120
(48.5 to 204)
75
(50 to 176)
<0.001
Serum ALT, U/L 39.5
(23 to 78)
38
(23 to 76)
49.5
(26 to 96.75)
0.001 52.5
(24.75 to 83.5)
46.5
(22.5 to 89.5)
48.5
(26.5 to 129.75)
0.1
PCT, ng/ml 0.59
(0.1 to 2.1)
0.5
(0.1 to 1.8)
2
(0.8 to 10)
0.001 2
(0.57 to 5.72)
8.3
(3.7 to 10.0)
2
(0.7 to 6.9)
<0.001
CRP, mg/ml 21.1
(12.2 to 44.8)
20
(12 to 42.1)
28
(16.8 to 61.2)
<0.01 34
(16.1 to 63.7)
29
(8.6 to 44.6)
25.8
(19.2 to 69)
0.08
aAKI, acute kidney injury; AKIN, Acute Kidney Injury Network; APACHE II, Acute Physiology and Chronic Health II; SD, standard deviation; SOFA, sequential organ
failure assessment; MV, mechanical ventilation; MODS, Multiple Organ Dysfunction Score; IQR, interquartile range; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; PCT, procalcitonin; CRP, C-reactive protein.
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virus has been previously reported in other forms of criti-
cal illness, particularly severe sepsis. Lopes et al. [23]
conducted a retrospective study of a cohort of 315
patients with sepsis admitted to the infectious diseases
ICU to determine the impact of AKI during ICU admis-
sion and found that AKI had a negative impact on in-
hospital mortality of patients with sepsis. As compared
with patients without acute renal impairment, patients
with AKI had a 25.3% increased probability of death.
Moreover, Lopes et al. found that the AKIN criteria were
a useful tool to characterize and stratify septic patients
according to the risk of death. In addition, the cause-
and-effect relationship between viral infection and kidney
AKI Stage: Mortality rate AKI Stage: Mortality rate
661 patients with 2009 H1N1 v
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i
t
y
C
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m
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18 8%
I
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18.8%
AKI
Figure 2 Intensive care unit (ICU) mortality among patients with pandemic 2009 influenza A (H1N1) virus infection and Acute Kidney
Injury Network (AKIN) criteria (No AKI, AKI I, AKI II, AKI III). Red dashed line represents the overall mortality.
Table 3 Outcomes of patients with pandemic 2009 influenza A (H1N1) virus infection. with or without AKI and AKIN
criteria
a
Variables Non AKI n = 543 AKI n = 118 P value AKI I n = 37 AKI II n = 15 AKI III n = 66 Total P value
ICU death, n (%) 72 (13.3%) 52 (44.1%) <0.001 9 (24.3%) 5 (33.3%) 38 (57.6%) 124 (18.8%) <0.001
MV days
b
Mean (±SD) 8.4 (11.5) 13.6 (15.2) <0.001 13.3 (17.6) 9.3 (11.8) 16.4 (12.5) 9.0 (12.0) 0.01
Median (IQR) 4 (0 to 12) 10 (3.75 to 21.5) 8 (3.25 to 20.75) 5 (0 to 14.5) 15 (5.5 to 26.5) 5 (0 to 13)
LOS ICU
c
Mean (±SD) 12.6 (13) 19.4 (16.5) <0.001 19.6 (18.4) 13.4 (11.5) 22.1 (15.3) 13.4 (13.6) <0.001
Median (IQR) 8 (4 to 17) 13 (7 to 30) 12 (7 to 29.5) 8 (5.5 to 19.5) 21.5 (7 to 75) 9 (4 to 18)
Hospital LOS
c
Mean (±SD) 20.5 (16.8) 30.3 (19.9) <0.001 29.3 (21.4) 23.0 (14.7) 36.0 (19.0) 21.6 (17.5) <0.001
Hospital median (IQR) 15 (9 to 27) 26.5 (13.75 to 44.25) 24.5 (13 to 44.5) 20 (10 to 34.5) 35 (19.5 to 49) 16 (9 to 29)
aAKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ICU, intensive care unit; MV, mechanical ventilation; IQR, interquartile range; LOS, length of stay; ICU,
intensive care unit; SD, standard deviation;
bonly survivors and mechanically ventilated;
conly survivors.
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has been implied by the patients’ clinical course in some
studies. One possible mechanism is glomerular deposi-
tion of viral antigens, which seems to be secondary to the
deposition of immune complexes. That is, the abnormal
expression of cytokine dysregulation associated with
severe viral infection injury might contribute to the renal
injury of H1N1 virus infection. Bermejo-Martin et al.
[25] recently reported an early secretion of Th17 and
Th1 cytokines in patients with severe H1N1 virus infec-
tion. In addition, To et al. [26] demonstrated a slower
control of viral load in patients with an exuberant cyto-
kine. Increased cytokines, together with lymphokines,
lead to the adhesion of inflammatory cells to endothe-
lium and other injury sites [27]. Endothelium-dependent
vasodilation is a prominent feature in patients with
moderate renal impairment [28], and plasma cytokine
levels could be useful in predicting mortality rates in cri-
tically ill patients with AKI.
H1N1 virus infection is associated with a high fatality
rate [1-4]; however, a potential explanation for such
rates has not been totally elucidated. Patients who
require ICU admission have frequently experienced
rapidly progressive, serious lower respiratory tract dis-
ease. Other well-recognized influenza complications in
these seriously ill patients with H1N1 virus infection
have included renal failure; however, the exact impact
has not been extensively investigated. In the first case
reports, impairment of renal function was commonly
described, and patients who died had documented mul-
tiple organ failure with significantly higher rates of renal
failure [29,30]. Myalgia is usually prominent early in the
illness, in contrast to available descriptions of influenza-
associated myositis, where onset occurs after or during
resolution of respiratory symptoms. Although direct
muscle invasion by the virus is one of the possibilities
suggested for virus-related rhabdomyolysis, not all the
patients who developed AKI showed high levels of CK.
In addition, AKI has been reported worldwide during
the last pandemic with very different incidences and a
paucity of robust AKI definitions. Data from Chile
reported that 25% of patients manifested elevated CK
levels. Sood et al. [31], in a cohort of 50 critically ill
patients, and Trimarchi et al. [32], in a study comprising
22 patients, reported an incidence around 65%. In our
Table 4 Comparison of demographic and clinical characteristics among with pandemic 2009 influenza A (H1N1) virus
infection
a
Variables Survivors (n = 527) Nonsurvivors (n = 134) P value
Mean age, yr (±SD) 43.2 (13.9) 46.09 (15.2) 0.1
Male sex, n (%) 290 (54.0%) 74 (59.7%) 0.2
Mean APACHE II score (±SD) 12.5 (5.9) 18.8 (7.9) <0.001
Mean SOFA score (±SD) 4.8 (2.8) 8.1 (4.3) <0.001
Comorbidities, n (%)
Pregnancy 33 (6.1%) 6 (4.8%) 0.6
COPD 94 (17.5%) 15 (12.1%) 0.1
Asthma 76 (14.2%) 11 (8.9%) 0.1
Heart failure 28 (5.2%) 11 (8.9%) 0.1
Obesity 194 (36.1%) 54 (43.5%) 0.1
Diabetes 56 (10.4%) 15 (12.1%) 0.6
Immunosuppression 13 (2.4%) 7 (5.6%) 0.07
Hematological disease 19 (3.5%) 15 (12.1%) <0.001
Neuromuscular disease 17 (3.2%) 6 (4.8%) 0.4
HIV infection 11 (2.0%) 4 (3.2%) 0.4
Invasive MV 290 (54.0%) 118 (95.2%) <0.001
Shock 208 (38.7%) 89 (71.8%) <0.001
MODS 299 (55.7%) 107 (86.3%) <0.001
Coinfection 76 (14.2%) 30 (24.2%) <0.01
aSurvivors versus nonsurvivors. APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, sequential organ failure assessment; COPD, chronic
obstructive pulmonary disease; HIV, human immunodeficiency virus; MV, mechanical ventilation; MODS, Multiple Organ Dysfunction Score.
Table 5 Multivariate logistic regression analysis: risk
factors for ICU mortality based on AKI criteria
a
Variables B Wald P value OR 95% CI
AKI
AKI I 0.42 0.79 0.37 1.52 0.61 to 3.81
AKI II 0.61 0.81 0.36 1.83 0.48 to 6.90
AKI III 1.57 15.06 0.000 4.81 2.17 to 10.62
APACHE II 0.05 5.87 0.01 1.06 1.01 to 1.11
Constant -5.19 60.58 0.00 0.00
aICU, intensive care unit; AKI, acute kidney injury; APACHE II, Acute Physiology
and Chronic Health Evaluation II; OR, odds ratio; CI, confidence interval; B, B
coefficient; Wald, Wald coefficient.
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Page 7 of 10study, 17.7% of patients developed AKI. Differences with
other studies might be related to our critically ill popu-
lation, for whom the criteria were standardized on the
basis of AKIN criteria. Finally, mortality rates of 16%,
19% and 54%, respectively, have been reported among
critically ill patients with H1N1 virus infection in Brazil
[33], Argentina [5] and Canada [3]. The main difference
is that in the present study, although the mortality rate
was 18.8% and significantly higher for patients who
developed AKI, multivariate analysis demonstrated that
only AKIN stage III was independently associated with
ICU mortality.
The present study has some limitations that should be
addressed. First, this is an observational, noninterventional
study in which 148 ICUs were selected. Management of
patients was not standardized, and management practices
were chosen in accordance with local protocols. Neverthe-
less, the study has the strength of being a prospective,
multicentered study with a large number of patients.
Second, in the present study, notes were not reviewed to
check for the context of patients’ clinical presentations,
and fluid resuscitation was not employed. In addition, the
information in regard to urine output and estimated base-
line CK levels was not used; this was the reason for the
choice of this system based on the AKIN criteria instead of
another other system of classification of AKI, such as risk,
injury, failure, loss, and end-stage kidney disease (RIFLE)
[34,35]. The degree of AKI classified by both the RIFLE
and AKIN criteria correlates with mortality in a progressive
fashion, emphasizing the importance of the severity of AKI.
Both classification systems help to standardize the defini-
tion and management of AKI. In the present analysis, the
AKIN criteria were chosen for analysis instead of the
RIFLE criteria. The choice of AKIN criteria may have been
driven by the lack of reliance on baseline CK levels, which
the RIFLE criteria do not take into consideration. Also, the
R I F L Ec r i t e r i ad on o tc o n s i d e rt h en a t u r eo rs i t eo ft h ek i d -
ney injury [36]. Finally, a potential bias might have
occurred because a diagnosis of AKI as a baseline hazard
ignores some patients who may have died very early, before
a diagnosis of AKI could be made. To avoid this potential
bias, the multivariate analysis was performed after exclud-
ing patients who died within the first 48 hours after ICU
a d m i s s i o na n da f t e ri tw a sc o n f i r m e dt h a tA K II I Iw a sa s s o -
ciated with a statistically significant worse outcome. In
addition, as reported by other authors [21], some patients
who were receiving CRRT would have been classified as
having AKI I or AKI II, which might have altered their out-
come. Future research seems mandatory to clarify the com-
plexities and confounding factors of AKI.
Conclusions
In summary, AKI represents a frequent complication in
critically ill patients with H1N1 virus infection and is
associated with increased mortality; however, only AKI
stage III was independently associated with worse out-
come. In addition, AKI was associated with increased
use of healthcare resources as manifested by increased
ICU and hospital LOS and more days under MV.
Key messages
￿ AKI represents a frequent complication in critically
ill patients with H1N1 virus infection.
￿ AKI development in critically ill patients with
H1N1 virus infection is associated with worse
outcome.
￿ Only critically ill patients affected by pandemic
H1N1 virus infection in stage AKI III are indepen-
dently associated with increased mortality.
￿ AKI development in critically ill patients affected
by H1N1 virus infection is associated with consump-
tion of increased health care resources manifested by
increased ICU and hospital LOS and more days
under mechanical ventilation.
￿ Prompt supportive measures are warranted in criti-
cally ill patients with H1N1 virus infection to
decrease the development of AKI.
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